References
- Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017; 3: 1683-91. doi: 10.1001/jamaoncol.2017.3055
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236. doi: 10.1016/j.jhep.2018.03.019
- Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv238-55. doi: 10.1093/annonc/mdy308
- Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-5. doi: 10.1016/j.jhep.2012.01.008
- European Association for the Study of the Liver, European Organisation for Research and Treatement of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J hepatol 2012; 56: 908-43. doi: 10.1016/j.jhep.2011.12.001
- Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol 2012; 81: 1173-8. doi: 10.1016/j.ejrad.2011.03.046
- Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81. doi: 10.1016/j.jhep.2006.10.020
- Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015; 61: 184-90. doi: 10.1002/hep.27443
- Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016; 64: 106-16. doi: 10.1002/hep.28453
- Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis 2016; 48: 571-7. doi: 10.1016/j.dld.2016.02.005
- Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52. doi: 10.1007/s00270-009-9711-7
- Floridi C, Radaelli A, Abi-Jaoudeh N, Grass M, Lin M, Chiaradia M, et al. C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications. Radiol Med 2014; 119: 521-32. doi: 10.1007/s11547-014-0429-5
- Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiol Oncol 2016; 50: 418-26. doi: 10.1515/raon-2015-0045
- Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol 2012; 35: 765-74. doi: 10.1007/s00270-012-0423-z
- Lencioni R, Llovet J. Modified RECIST (mRECIST) Assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60. doi: 10.1055/s-0030-1247132
- Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-14. doi: 10.1016/S0140-6736(11)61347-0
- Llovet J, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42. doi: 10.1053/jhep.2003.50047
- Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 2010; 42(Suppl 3): S258-63. doi: 10.4254/wjh.v7.i9.1184
- Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology 2020; 72: 198-212. doi: 10.1002/hep.31022
- Xiao J, Li G, Lin S, He K, Lai H, Mo X, et al. Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization. Int J Clin Exp Pathol 2014; 7: 1114-23. PMID: 24696728
- Chen S, Peng Z, Zhang Y, Chen M, Li J, Guo R, et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: Abandon or repeat? Radiology 2021; 298: 680-92. doi: 10.1148/radiol.2021202289
- Olivo M, Valenza F, Buccellato A, Scala L, Virdone R, Sciarrino E, et al. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis 2010; 42: 515-9. doi: 10.1016/j.dld.2009.09.012
- Suk Oh J, Jong Chun H, Gil Choi B, Giu Lee H. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response. J Vasc Interv Radiol 2013; 24: 483-9. doi: 10.1016/j.jvir.2013.01.001
- Ikeda M, Inaba Y, Tanaka T, Sugawara S, Kodama Y, Aramaki T, et al. A prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: The JIVROSG-1302 PRESIDENT study. [Abstract]. JCO 2020; 38(15 Suppl): 4518. doi: 10.1200/jco.2020.38.15_suppl.4518
- Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin Intervent Radiol 201; 28: 207-11. doi: 10.1055/s-0031-1280666
- Rashid M, Kwok CS, Pancholy S, Chugh S, Kedev SA, Bernat I, et al. Radial artery occlusion after transradial interventions: a systematic review and meta-analysis. J Am Heart Assoc 2016; 5: e002686. doi: 10.1161/JAHA.115.002686
- Zach V, Rapaport B, Yoo JY, Goldfeder L, Weinberger J. Multiple ischemic strokes after transcatheter arterial chemoembolization for hepatocellular carcinoma with a radiographic and pathological correlate. J Stroke Cerebrovasc Dis 2012; 21: 217-24. doi: 10.1016/j.jstrokecerebrovas-dis.2010.08.001
- Onizuka H, Sueyoshi E, Ishimaru H, Sakamoto I, Uetani M. Arterial injury during transcatheter arterial chemoembolization for hepatocellular carcinoma: predictors of risk and outcome. Abdom Radiol (NY) 2017; 42: 2544-50. doi: 10.1007/s00261-017-1168-6